NeuroMetrix, Inc. (NURO)

Market Cap	11.38M
Revenue (ttm)	8.26M
Net Income (ttm)	-4.42M
Shares Out	7.79M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,141
Open	1.44
Previous Close	1.44
Day's Range	1.42 - 1.48
52-Week Range	1.33 - 5.89
Beta	2.31
Analysts	Buy
Price Target	n/a
Earnings Date	Apr 25, 2023

About NURO

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1996
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: NURO

Financial Performance

In 2022, NeuroMetrix's revenue was $8.26 million, an increase of 0.03% compared to the previous year's $8.25 million. Losses were -$4.42 million, 93.6% more than in 2021.